Photocure ASA

Board/Management Information • Mar 26, 2025

Photocure appoints Jane Healy as Vice President and General Manager EMEA

Photocure appoints Jane Healy as Vice President and General Manager EMEA

Press Release - Oslo, Norway, March 26, 2025: Photocure ASA (OSE: PHO), the

Bladder Cancer Company, today announced the appointment of Jane Healy as Vice

President and General Manager EMEA.

Ms. Healy joined Photocure in March 2025 to lead the European Organization. Her

extensive international experience in the medical device field covers sales,

marketing, general management and functional leadership. Over the past 30 years

she has worked for three major medical device organizations; St Jude Medical, CR

Bard and over 20 years for Boston Scientific.

In her most recent role, Jane Healy was VP EMEA for the Peripheral Interventions

Division for Boston Scientific, responsible for driving the growth strategy for

the region. She brings a blend of strong commercial acumen, results orientation

and a passion for enabling and driving results through her teams. Jane Healy

holds a BA (Hons) in Modern Languages from Cambridge University and she speaks

English, French, German and Italian.

"I am pleased to welcome Jane to the Photocure team at such an important time

for us. Her background and extensive experience in healthcare and medical

devices will be instrumental in achieving our growth ambitions in uro-oncology.

Her track record of building successful international teams make her the ideal

fit to lead Photocure's European Organization, at a time when the Uro-Oncology

world is experiencing tremendous innovation and attention in healthcare. Jane

will report directly to me in her role as GM EMEA and will be a member of

Photocure's executive leadership team. says Dan Schneider, President and Chief

Executive Officer of Photocure.

Photocure's European Organization was launched following the agreement to regain

the Hexvix[®] sales, marketing and distribution rights in Europe and other

markets from Ipsen Pharma SAS on 1 October 2020. The European team has gained

momentum since re-introducing BLC to the European market.

"I am pleased with the ongoing developments in Europe and look forward to Jane's

leadership as we continue pursuing our ambition to lead the change that will

improve the lives of bladder cancer patients. We know the importance of using

Blue Light Cystoscopy in the precision diagnostic pathway for bladder cancer,

where accurate staging and resection helps determine the optimal treatment

decisions", Schneider concludes.

Note to editors:

All trademarks mentioned in this release are protected by law and are registered

trademarks of Photocure ASA.

This press release may contain product details and information which are not

valid, or a product is not accessible, in your country. Please be aware that

Photocure does not take any responsibility for accessing such information which

may not comply with any legal process, regulation, registration or usage in the

country of your origin.

About Bladder Cancer

Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most

common in men - with 1 949 000 prevalent cases (5-year prevalence rate)[1a],

614 000 new cases and more than 220 000 deaths in 2022.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high

recurrence rate with up to 61% in year one and up to 78% over five years.[2]

Bladder cancer has the highest lifetime treatment costs per patient of all

cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients

have to undergo multiple cystoscopies due to the high risk of recurrence. There

is an urgent need to improve both the diagnosis and the management of bladder

cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer

(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of

invasion in the bladder wall. NMIBC remains in the inner layer of cells lining

the bladder. These cancers are the most common (75%) of all BC cases and include

the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has

grown into deeper layers of the bladder wall. These cancers, including subtypes

T2, T3 and T4, are more likely to spread and are harder to treat.[4]

[1 ]Globocan. a) 5-year prevalence / b) incidence/mortality by population.

Available at: https://gco.iarc.fr/today, accessed [February 2024].

[2 ]Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657

[3 ]Sievert KD et al. World J Urol 2009;27:295-300

[4 ]Bladder Cancer. American Cancer Society.

https://www.cancer.org/cancer/bladder-cancer.html

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the

bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC

with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves

the detection of tumors and leads to more complete resection, fewer residual

tumors, and better management decisions.

Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all

other markets. Photocure is commercializing Cysview/Hexvix directly in the U.S.

and Europe and has strategic partnerships for the commercialization of

Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer

to https://photocure.com/partners/our-partners for further information on our

commercial partners.

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to

improve the lives of bladder cancer patients. Our unique technology, making

cancer cells glow bright pink, has led to better health outcomes for patients

worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo

Stock Exchange (OSE: PHO). For more information, please visit us at

www.photocure.com/news

For further information, please contact:

Dan Schneider

President and CEO

Photocure ASA

Email: ds@photocure.com

Erik Dahl

CFO

Photocure ASA

Tel: +4745055000

Email: ed@photocure.com

Media and IR enquiries:

Geir Bjørlo

Corporate Communications (Norway)

Tel: +47 91540000

Email: geir.bjorlo@corpcom.no